Novartis is now matching the price tag of its CAR-T therapy Kymriah with rival Gilead’s Yescarta pricing, although there will no longer be any outcomes-based stipulations.
In the latest indication OK’d by the U.S. Food and Drug Administration, the drugmaker has priced the treatment at $373,000, matching Gilead’s pricing for its therapy, pharmaphorum reports.
Novartis originally priced the treatment for B-cell acute lymphoblastic leukemia at $475,000 with a money-back guarantee to care providers if the treatment failed.
Novartis head of cell and gene oncology Pascal Touchon said the outcomes-based arrangement was dropped due to the difficulty of measuring patient outcomes with Kymriah.
To read the full report on pharmaphorum, click here.